TABLE 6.
Different ADRs among Enfortumab vedotin and Erdafitinib.
| System organ classes | Enfortumab vedotin | Erdafitinib |
|---|---|---|
| Blood and lymphatic system disorders | Eosinophilia, lymphopenia, febrile neutropenia, pancytopenia, febrile bone marrow aplasia, bone marrow failure, haematotoxicity, lymphadenopathy, neutropenia, cytopenia, and leukopenia | Monocytosis |
| Cardiac disorders | Myocardial infarction, atrial fibrillation, and cardiac arrest | Atrioventricular block second degree |
| Endocrine disorders | Hypothyroidism | Thyroid disorder |
| Eye disorders | Eye irritation, eye pruritus, and blepharitis | Corneal thinning, retinopathy, eye swelling, maculopathy, central serous chorioretinopathy, chorioretinopathy, retinal oedema, retinal detachment, ulcerative keratitis, detachment of retinal pigment epithelium, serous retinal detachment, cataract, and blindness |
| Gastrointestinal disorders | Abdominal discomfort, small intestinal obstruction, and pancreatitis | Oral pain, rectal haemorrhage, lip pain, oral discomfort, chapped lips, mouth ulceration, intestinal obstruction, aphthous ulcer, and ascites |
| General disorders and administration site conditions | Therapy partial responder, oedema peripheral, extravasation, multiple organ dysfunction syndrome, gait disturbance, administration site extravasation, pyrexia, chills, and infusion site extravasation | Xerosis, adverse event, discomfort, mucosal disorder, drug intolerance, illness, adverse drug reaction, therapeutic product effect decreased, and adverse reaction |
| Hepatobiliary disorders | Hepatic cytolysis, hyperbilirubinaemia hypertransaminasaemia, and hepatic function abnormal | Drug-induced liver injury and cholangitis |
| Infections and infestations | Oral candidiasis, erysipelas, cellulitis, pneumonia aspiration, device related infection, clostridium difficile colitis, escherichia urinary tract infection, septic shock, and urosepsis | Paronychia, nail infection, nail bed infection, oral fungal infection, onychomycosis, haematological infection, and retinitis |
| Injury, poisoning and procedural complications | Infusion related reaction, underdose, and intercepted product storage error | Product use complaint, wrong technique in product usage process, intentional product use issue, medication error, product prescribing error, product dose omission issue, fracture, and product dispensing error |
| Investigations | Blood glucose abnormal, haemoglobin decreased, heart rate increased, white blood cell count increased, blood glucose increased, neutrophil count decreased | Blood phosphorus increased, liver function test abnormal, platelet count decreased, blood sodium decreased, lymphocyte count decreased, general physical condition abnormal, blood urine present, and white blood cell count decreased |
| Metabolism and nutrition disorders | Insulin resistance, hyperglycaemia, ketoacidosis, hypomagnesaemia, diabetic metabolic decompensation, hypophagia, hypokalaemia, diabetes mellitus, hypocalcaemia, diabetic ketoacidosis, and diabetes mellitus inadequate control | Hypoalbuminaemia, hyperphosphataemia, feeding disorder, and calciphylaxis |
| Musculoskeletal and connective tissue disorders | Back pain, mobility decreased, and muscular weakness | Muscle spasms, growth accelerated, tendon disorder, and bone pain |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Metastases to lung, and metastases to bone | Metastases to central nervous system, transitional cell carcinoma, metastatic carcinoma of the bladder, neoplasm, metastatic neoplasm, neoplasm malignant, brain neoplasm malignant, and malignant neoplasm of renal pelvis |
| Nervous system disorders | Hypoaesthesia, chronic inflammatory demyelinating polyradiculoneuropathy, peripheral sensory neuropathy, polyneuropathy, neuralgia, peripheral sensorimotor neuropathy, neurotoxicity, encephalopathy, peripheral motor neuropathy, and cognitive disorder | Central nervous system lesion, hyperaesthesia, syncope, spinal cord compression, cerebrovascular accident, mental impairment, and myelopathy |
| Product issues | Product temperature excursion issue | Product availability issue |
| Psychiatric disorders | Delirium | Eating disorder |
| Renal and urinary disorders | Haematuria, and tubulointerstitial nephritis | Urinary retention |
| Respiratory, thoracic and mediastinal disorders | Immune-mediated lung disease, dyspnoea exertional, respiratory failure, lung opacity, aspiration, lung disorder, and acute respiratory failure | Throat tightness, nasal dryness, haemoptysis, dry throat, pleural effusion, pulmonary oedema, epistaxis, and oropharyngeal discomfort |
| Skin and subcutaneous tissue disorders | Stevens-johnson syndrome, skin lesion, rash maculo-papular, rash vesicular, toxic skin eruption, skin reaction, toxic epidermal necrolysis, dermatitis bullous, symmetrical drug-related intertriginous and flexural exanthema, rash erythematous, rash pruritic, and skin discolouration | Onychomadesis, skin disorder, nail dystrophy, nail toxicity, nail discomfort, skin fissures, nail disorder, nail discolouration, palmar-plantar erythrodysaesthesia syndrome, onychoclasis, onychalgia, and onycholysis |
| Surgical and medical procedures | Therapy cessation, spinal operation, hospice care, surgery, therapy change, therapy interrupted, and hospitalisation | |
| Vascular disorders | Hypertension, and shock | Deep vein thrombosis, embolism, dry gangrene, and thrombosis |